Portland, ORNCT03649880Now EnrollingIRB Ready

Malignant Brain Neoplasm Clinical Trial in Portland, OR

Access cutting-edge malignant brain neoplasm treatment through this clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.

Sponsored by OHSU Knight Cancer Institute

Quick Self-Assessment

See if you qualify for this Portland location

Preparing your pre-screening questions…

Expert Care in Portland

Access malignant brain neoplasm specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related malignant brain neoplasm treatment provided free

Apply for This Portland Location

Check if you qualify for this malignant brain neoplasm clinical trial in Portland, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Portland

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Portland site if eligible
  4. 4Begin participation

About This Malignant Brain Neoplasm Study in Portland

This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.

Sponsor: OHSU Knight Cancer Institute

Who Can Participate

Inclusion Criteria

Adult patients (greater than 18 years of age) with a known or suspected intracranial tumor.
Able to provide informed written consent and/or acceptable surrogate capable of providing consent on the patient's behalf.
Legally authorized representative (LAR)-signed informed consent and assent obtained for those subjects identified as decisionally impaired
Intracranial lesion known or suspected to be neoplastic greater than 10 mL as assessed by T2/fluid attenuated inversion recovery (FLAIR) MR imaging.
Karnofsky performance score \> 60 or Eastern Cooperative Oncology Group (ECOG) \< 3 as assessed by referring clinician.
Planning to undergo or previously received therapeutic intervention for the intracranial tumor.

Exclusion Criteria

Pregnant or breast feeding.
Contraindication to PET, MRI, FMISO, or intravenous gadolinium based contrast agents.
Claustrophobia.
Weight greater than modality maximum capacity.
Presence of metallic foreign body or implanted medical devices in body not documented as MRI safe according to the Oregon Health \& Science University (OHSU) Department of Radiology guidelines (including but not limited to cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants).
Sickle cell disease.
Reduced renal function, as determined by glomerular filtration rate (GFR) \< 45 mL/min/1.73 m\^2 based on a serum creatinine level obtained per OHSU Department of Radiology and Advanced Imaging Research Center (AIRC) clinical criteria.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to FMISO. An allergic reaction to nitroimidazoles is highly unlikely.
Unsure of pregnancy status as assessed by Department of Radiology and AIRC guidelines.
Subjects for whom supplemental oxygen could be harmful such as people with potential for hypoventilation (end-stage COPD, OSA on CPAP/Bi-PAP, etc).
Subjects with a relative contraindication to supplemental oxygen administration will not be provided oxygen but may still participate in the study.
Presence of any other co-existing condition that, in the judgment of the principal investigator, might increase the risk to the subject (i.e., plans for hospice or end of life care).
Poor peripheral intravenous access evaluated by patient history.
Presence of other serious systemic illnesses, including: uncontrolled infection, other uncontrolled malignancy, uncontrolled diabetes type II, or psychiatric/social situations which might impact the endpoint of the study or limit compliance with study requirements.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT03649880) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Malignant Brain Neoplasm Treatment Options in Portland, OR

If you're searching for malignant brain neoplasm treatment options in Portland, OR, this clinical trial (NCT03649880) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced malignant brain neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all malignant brain neoplasm clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Portland, OR

See all rheumatoid arthritis clinical trials recruiting in Portland — not just this study.

Browse Rheumatoid Arthritis Trials in Portland →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Portland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Portland, OR